Background and Hypothesis: Japan is an aging society, and the number of nonage-
Transcatheter aortic valve implantation (TAVI) has emerged as a less invasive alternative to SAVR in patients with severe AS who cannot undergo surgery, or who are at intermediate/high surgical risk, resulting in acceptable clinical outcomes. [3] [4] [5] [6] [7] [8] Japan is an aging society, and the number of nonagenarians with severe AS undergoing TAVI is increasing, but their outcomes have not been determined fully.
Vendrik et al 9 reported the 5-year outcomes of European nonagenarians who underwent TAVI. Moreover, Miura et al 10 reported on the early outcomes of Japanese nonagenarians who underwent TAVI, but they did not evaluate long-term outcomes. In this study, we evaluated the long-term outcomes of Japanese nonagenarians who underwent TAVI.
2 | METHODS
| Study patients
We prospectively enrolled 767 consecutive patients with severe symptomatic AS who presented to Sakakibara Herat Institute (n = 625), Yamagata University Hospital (n = 42), or Juntendo University Hospital (n = 100), all of which are located in Japan, between April 2010 and September 2018 and underwent TAVI. This study protocol was conducted according to the principles of the Declaration of Helsinki and approved by the ethics committees of each of these three institutions.
The decision to undertake TAVI was made by the Cardiac Teams (cardiologists, cardiac surgeons, radiologists, and anesthesiologists) of each institution. All patients were considered to be "high-risk" cases and not suitable for SAVR by the Cardiac Teams. The Society of Thoracic Surgeons predictive risk of mortality, the logistic European System for Cardiac Operative Risk Evaluation (Logistic EuroScore), and Euro II Score were evaluated for preoperative risk. Moreover, the Clinical Frailty Scale (CFS), major organ dysfunction (including the respiratory system) and procedure-specific impediments were evaluated to confirm patient status not reflected in preoperative risk scores according to the 2014 American Heart Association/American College of Cardiology guidelines for the management of valvular heart disease.
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The transfemoral approach was the primary procedure. Selection and sizing of the device were based on multi-slice computed tomography by each Cardiac Team. Other access sites (eg, transapical or transsubclavian artery) were considered if the transfemoral approach was not suitable for advancing the large sheath.
| Endpoints
The primary endpoint of our study was all-cause mortality after TAVI.
Moreover, we evaluated early safety endpoints (all-cause mortality, stroke, life-threatening bleeding, acute kidney injury, coronary artery obstruction, major vascular complications, and valve-related dysfunction requiring repeat procedure) according to Valve Academic
Research Consortium 2 (VARC-2) criteria. 12 Information regarding patient survival was obtained from each institution where TAVI was done or through telephone calls directly to patients/patients' families according to the criteria of the ethics committee of each participating institution.
| Statistical analyses
Continuous variables are the mean ± SD or median (interquartile range 
| TAVI
The procedural characteristics of TAVI are summarized in Table 2 . A transfemoral approach was taken in 678 (88%) patients, and there were no significant differences in approach between the two groups.
In the patients with transfemoral approach, 100 patients (15%) were treated with cutdown approach. Moreover, about half of all patients were treated with general anesthesia, and there were no significant differences in anesthesia methods between the two groups. Of 767 patients, 745 (97%) achieved device success, and device success was lower in nonagenarians than in non-nonagenarians (94% vs 98%, P < .05). In nonagenarians, six patients (6%) did not achieve device success: one patient died due to annulus rupture; three patients did not achieve correct positioning of a single prosthetic heart valve into the appropriate anatomic location; two patients did not achieve the intended performance of the prosthetic heart valve. In patients aged <90 years, 16 patients (2%) did not achieve device success: one patient died due to acute limb ischemia; 10 patients did not achieve correct positioning of a single prosthetic heart valve into the Previous stroke, n (%) 83 (11) 6 (6) 77 (11) .16
Previous myocardial infarction, n (%) 44 (6) 3 (3) 41 (6) .35
Previous coronary intervention, n (%) 139 (18) 18 (19) 121 (18) .78
Previous bypass surgery, n (%) 49 (6) 2 (2) 47 (7) .07 COPD, n (%) 55 (7) 9 (10) 46 (7) .39
Atrial fibrillation/flutter, n (%) 180 (23) 27 (29) 153 (23) .20
Peripheral vascular disease, n (%) 119 (16) 14 (15) 105 (16) 1.0
Permanent pacemaker, n (%) 45 (6) 7 (7) 38 (6 appropriate anatomic location; five patients did not achieve the intended performance of the prosthetic heart valve.
| Early outcomes
Early outcomes are summarized in Table 3 . Five patients died of any cause 30 days after TAVI. Survival at 30 days tended to be lower in nonagenarians compared with non-nonagenarians but not significantly so (97.9% in nonagenarians vs 99.6% in non-nonagenarians; log-rank test, P = .06) ( Figure 1A ). Early safety according to VARC-2 criteria was 10%, and there was no significant difference between the two groups ( Figure 1B ). The prevalence of stroke, life-threatening bleeding, acute kidney injury (stage 2 or 3), coronary artery obstruction or valve-related dysfunction was similar in both groups. A major vascular complication was significantly more prevalent in nonagenarians than in non-nonagenarians (19% vs 1%, P < .05). The duration of hospital stay after TAVI was similar in both groups (10 [7-18] in nonagenarians vs 9 [7] [8] [9] [10] [11] [12] [13] [14] days in non-nonagenarians).
| Long-term mortality
Long-term mortality was evaluated by the log-rank test ( Figure 1C ).
Freedom from any cause of death 3 years after TAVI was not significantly different between the two groups (77.9% in nonagenarians vs 82.5% in non-nonagenarians, P = .25), and the cause of death (cardiovascular death or non-cardiovascular death) was mentioned in Table 3 .
| Predictors of all-cause mortality
We performed multivariate Cox proportional hazard analyses to evaluate the predictors of all-cause mortality 3 years after TAVI (Table 4) . 
T A B L E 2 TAVI characteristics
Note. "Early safety" was defined as the composite endpoint according to VARC-2 criteria.
| DISCUSSION
In this three-center study, we evaluated the long-term outcomes of Japanese nonagenarians who underwent TAVI. Main findings were that:
(a) patients aged ≥90 years tended to have higher 30-day mortality in comparison with those with aged <90 years; (b) early safety was similar between patients aged ≥90 years and those aged <90 years; (c) there was no significant difference in 3-year outcomes between patients aged ≥90 years and those aged <90 years; (d) age ≥ 90 years was not a predictor for all-cause mortality. Nonagenarians had a slightly higher prevalence of short-term mortality, but there was not significantly different in longterm mortality between nonagenarians and non-nonagenarians. Hence, caution in selecting TAVI for nonagenarians might be unwarranted.
There were few differences in preoperative comorbidities as evaluated by the CFS between nonagenarians and non-nonagenarians.
Considering these results, it appears that the nonagenarians in this study are self-selected patient populations who have selecting bias.
Age is an important prognostic factor and should be taken into consideration, but comorbidities or functional status have been shown to be better predictors of mortality. 13 We think that careful evaluation of patients and their risk factors before TAVI is very important for preventing postoperative complications, morbidity and mortality.
Several researchers have reported worse short-term mortality in nonagenarians who underwent TAVI compared with that in nonnonagenarians, but acceptable long-term outcomes have been reported, especially for patients who underwent TAVI using a transfemoral approach. 9, [14] [15] [16] [17] [18] Those results support our data showing that patients aged ≥90 years tended to have higher 30-day mortality in comparison with those aged <90 years, but there was no significant difference in 3-year outcome in our study.
TAVI-based complications and postoperative morbidity might affect the quality of life of nonagenarians who undergo TAVI. Vascular problems are common and frequent complications of TAVI. Similar to previous studies, we found that major vascular complications were more frequent in nonagenarians than in patients aged <90 years. 14, 19 The prevalence of life-threatening bleeding was similar in both groups, and the proportion of patients who needed transfusion for any reason was not significantly different between patients aged ≥90 (21%) and those aged <90 years (24%). In contrast, Havakuk et al 20 reported a F I G U R E 1 Kaplan-Meier curves of: A, All-cause mortality at 30 days stratified by the age at procedure; B, Early safety endpoints stratified by the age at procedures, and C, All-cause mortality at 3 years stratified by the age at procedure T A B L E 4 Adjusted hazard ratios for all-cause mortality 3 years after TAVI showed that age ≥ 90 years was not a predictor of long-term mortality. We believe that hesitation in assigning nonagenarians to TAVI might be unwarranted, though consensus on evaluation of adaptation to TAVI by Cardiac Teams is needed.
In the present study, about half of all patients were treated by local anesthesia with mild sedation and without intubation. Benefits of local anesthesia include early recovery and risk reduction of hemodynamic instability during TAVI. Local anesthesia with mild sedation is favored, especially in nonagenarians, because they need a shorter stay in hospital to recover early after TAVI. It is thought that local anesthesia with mild sedation will aid better outcomes for nonagenarians who undergo TAVI.
Our study had two main limitations. First, there was selection bias among nonagenarians. No data were available among nonagenarians who did not undergo TAVI. Second, our study cohort was small, so further large-scale studies are clearly warranted.
| CONCLUSIONS
TAVI could be carried out safely and effectively in nonagenarians, and they had acceptable long-term results compared with non-nonagenarians, although careful attention should be paid to major vascular complication.
CONFLICT OF INTEREST
The authors declare no potential conflict of interests.
ORCID

Hiroaki Yokoyama
https://orcid.org/0000-0001-6452-6413
